R&D channel feed – Endpoints News

R&D channel feed

Sio Gene Therapies posts positive PhI/II data in rare pediatric disease, the first readout since its name change

5 years ago

Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortality data

5 years ago

Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema

5 years ago

Allogene, Overland plot speedy Asia play for off-the-shelf CAR-T with $117M joint venture

5 years ago

AbbVie pulls the trigger on a Covid-19 antibody, going all in on a drug discovered by research alliance

5 years ago

MassBio head Coughlin set to step down after overseeing massive biopharma expansion in the state during 13-year tenure

5 years ago

After scoring big Pfizer buyout, a Therachon co-founder turns once again to dwarfism with $24M Series A

5 years ago

Savara shuts down another cystic fibrosis program after a PhIII flop, as it prepares to axe staff and re-center around aPAP

5 years ago

Sanofi, GlaxoSmithKline hit with a major delay on Covid-19 vaccine program as their first jab flops in older adults

5 years ago

Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt

5 years ago

Angling for a spot among the giants, TG Therapeutics touts PhIII MS data for CD20 drug

5 years ago

Eli Lilly is rapidly approaching its Trulicity doomsday, but it may have a nice consolation prize in tirzepatide

5 years ago

Little Evelo sees big promise in its first cut of data from a tiny study on atopic dermatitis

5 years ago

Novartis' CDK4/6 med Kisqali, firmly the sales underdog against Pfizer's Ibrance, drops big OS data

5 years ago

AbbVie chases its next golden goose in a post-Humira future with new ulcerative colitis data for Rinvoq

5 years ago

In another blow to MSCs developer, Pluristem terminates a failed lead program

5 years ago

Advocacy group accuses FDA neuro chief Billy Dunn of misconduct in controversial Biogen review, demands a purge and federal probe

5 years ago

Beating Merck, Pfizer gets priority review as the first Prevnar follow-up heads to the FDA

5 years ago

#ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival

5 years ago

A KRAS drug is likely coming — fast — as the FDA points Amgen’s frontrunner to a looming finish line

5 years ago

#ASH20 saw a BCMA brawl. Who's still standing? And who got knocked out for good?

5 years ago

BioCryst bags $250M in a debt and royalty deal as the executive team preps a new drug launch for HAE

5 years ago

Updated: #ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $2.75B buyout

5 years ago

#ASH20: Bain execs step in to position a somewhat battered and bruised Syros with a new clinical candidate and enough money to charge ahead

5 years ago

First page Previous page 180 181 182183184 185 186 Next page Last page